Targeting rapid action of sex steroid receptors in breast and prostate cancers.

Human breast and prostate cancers are complex diseases caused by the progressive accumulation of gene mutations combined with epigenetic deregulation of critical genes and derangement of signaling pathways. Compelling evidence indicates that steroid hormones elicit non-genomic responses in cytoplasm of target cells. In this cellular location, steroid-coupled receptors recruit signaling effectors or scaffold proteins, thereafter activating multiple pathways leading to proliferation, survival, migration and invasiveness. Thus, the immediate challenge is the dissection of key upstream events regulating steroid response in target tissues to prevent progression and improve treatment of breast and prostate cancers. Progress in our understanding of the molecular mechanisms that play a master role in these cancers has strongly stimulated the search for specific inhibitors of key signaling molecules. This review aims to give an up-to-date report of the complex network regulating non-genomic action of steroid hormones in target cells. The final section highlights recent advances from our laboratory and future directions in alternative approaches for the treatment of breast and prostate cancers.

[1]  J. Davis,et al.  Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Edwards,et al.  Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. , 2007, Molecular endocrinology.

[3]  D. Yee,et al.  Progesterone and Breast Cancer , 2008, Women's health.

[4]  E. Levin.  Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.

[5]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[6]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[7]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[8]  D. Bostwick,et al.  Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. , 2006, The Journal of urology.

[9]  T. Wurch,et al.  Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. , 2007, European journal of cancer.

[10]  D. Edwards,et al.  The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. , 2007, Molecular endocrinology.

[11]  Helmut Klocker,et al.  Rapid signalling by androgen receptor in prostate cancer cells , 1999, Oncogene.

[12]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[13]  M. Beato,et al.  Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. , 2006, Molecular cell.

[14]  A. Bilancio,et al.  PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cells , 2001, The EMBO journal.

[15]  C. Sternberg,et al.  Role of targeted therapy in the treatment of advanced prostate cancer , 2010, BJU international.

[16]  G. Castoria,et al.  Signaling-dependent nuclear export of estradiol receptor controls cell cycle progression in breast cancer cells , 2009, Molecular and Cellular Endocrinology.

[17]  E. Levin,et al.  Extranuclear steroid receptors: nature and actions. , 2007, Endocrine reviews.

[18]  D. Edwards,et al.  Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. , 2001, Molecular cell.

[19]  S. Haslam,et al.  Effects of epidermal growth factor, estrogen, and progestin on DNA synthesis in mammary cells in vivo are determined by the developmental state of the gland , 1993, Journal of cellular physiology.

[20]  Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. , 2000, Molecular endocrinology.

[21]  Andrea Riccardo Genazzani,et al.  Extra-Nuclear Signalling of Estrogen Receptor to Breast Cancer Cytoskeletal Remodelling, Migration and Invasion , 2008, PloS one.

[22]  E. Yong,et al.  Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Pagano,et al.  Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. , 1993, Oncogene.

[24]  I. Treilleux,et al.  Regulation of estrogen rapid signaling through arginine methylation by PRMT1. , 2008, Molecular cell.

[25]  G. Castoria,et al.  Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic implications. , 2007, The international journal of biochemistry & cell biology.

[26]  Wen-rong Gong,et al.  Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross‐talk with estrogen receptor , 1998, The EMBO journal.

[27]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[28]  E. Appella,et al.  Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth , 2007, Oncogene.

[29]  E. Appella,et al.  Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells , 2008, The Journal of cell biology.

[30]  C. Lange,et al.  Progesterone Receptors Upregulate Wnt-1 To Induce Epidermal Growth Factor Receptor Transactivation and c-Src-Dependent Sustained Activation of Erk1/2 Mitogen-Activated Protein Kinase in Breast Cancer Cells , 2006, Molecular and Cellular Biology.

[31]  V. Speirs,et al.  Oestrogen receptor β: what it means for patients with breast cancer , 2004 .

[32]  A. Belfiore,et al.  Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. , 2009, Cancer research.

[33]  M. Beato,et al.  Two Domains of the Progesterone Receptor Interact with the Estrogen Receptor and Are Required for Progesterone Activation of the c-Src/Erk Pathway in Mammalian Cells , 2003, Molecular and Cellular Biology.

[34]  A. Bilancio,et al.  Role of Atypical Protein Kinase C in Estradiol-Triggered G1/S Progression of MCF-7 Cells , 2004, Molecular and Cellular Biology.

[35]  W. Tilley,et al.  Breast and prostate cancer: more similar than different , 2010, Nature Reviews Cancer.

[36]  Toby J Gibson,et al.  Cell regulation: determined to signal discrete cooperation. , 2009, Trends in biochemical sciences.

[37]  M. Beato,et al.  Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells. , 2005, Molecular endocrinology.

[38]  L. Silengo,et al.  p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells , 2004, Journal of Cell Science.

[39]  S. Yeh,et al.  Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor , 2003, The Journal of experimental medicine.

[40]  M. Freeman,et al.  Phosphoinositide 3-Kinase-independent Non-genomic Signals Transit from the Androgen Receptor to Akt1 in Membrane Raft Microdomains* , 2007, Journal of Biological Chemistry.

[41]  Y. Wang,et al.  A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells , 2007, Oncogene.

[42]  Yuzhuo Wang,et al.  Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  C. J. Barnes,et al.  A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.